TS
TGTX icon

Thomas Steyer’s TG Therapeutics TGTX Stock Holding History

Thomas Steyer’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-500,000
Closed -$19.4M – 313
2021
Q2 		$19.4M Hold
500,000
– – 0.08% 103
2021
Q1 		$24.1M Buy
500,000
+400,000
+400% +$19.2M 0.12% 97
2020
Q4 		$5.2M Buy
+100,000
New +$3.38M 0.03% 122
2020
Q3 		– Sell
-1,500,000
Closed -$29.2M – 135
2020
Q2 		$29.2M Buy
+1,500,000
New +$24.2M 0.23% 74

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thomas Steyer's TGTX Position: Q3 2021 in Review

Thomas Steyer sold out of TG Therapeutics (TGTX) in Q3 2021, closing a stake of 500,000 shares — an estimated $19.4M sold.

Thomas Steyer first reported a position in TGTX in Q2 2020 and held it in 4 quarters. The position peaked at $29.2M in Q2 2020. 222 funds tracked by Wall St. Rank hold TGTX as of Q3 2021.

  • Thomas Steyer reported no remaining TG Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Thomas Steyer sold 500,000 TG Therapeutics shares in Q3 2021, an estimated $19.4M.
  • Thomas Steyer first reported a position in TG Therapeutics in Q2 2020 and held it in 4 quarters.
  • Thomas Steyer's TG Therapeutics position peaked at $29.2M in Q2 2020.
  • 222 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2021.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.